Related Experiment Video

Updated: Aug 4, 2026

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
08:16

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?

S Dukic-Stefanovic1, R Schinzel, P Riederer

  • 1Physiological Chemistry I, Biocenter, University of Würzburg, Germany.

Biogerontology
|November 16, 2001
PubMed

Insights

Advanced Glycation End-products (AGEs) worsen Alzheimer's disease (AD) by impairing cellular functions and increasing oxidative stress. AGE-inhibitors show potential as novel therapeutic drugs for AD treatment.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Alzheimer's disease (AD) involves age-related cellular dysfunction, exacerbated by Advanced Glycation End-products (AGEs).
  • Intracellular AGEs, likely from methylglyoxal, crosslink proteins, forming insoluble aggregates that disrupt neuronal transport and function.
  • Extracellular AGEs accumulate in aging tissues and amyloid plaques, inducing oxidative stress and glial cell activation.

Purpose of the Study:

  • To investigate the role of AGEs and carbonyl stress in Alzheimer's disease progression.
  • To explore the potential therapeutic benefits of AGE-inhibitors in AD.

Main Methods:

  • Analysis of AGEs' impact on cellular processes in AD models.
  • Review of existing AGE-inhibitor efficacy in other conditions (e.g., diabetic complications).

Main Results:

  • AGEs contribute to neuronal dysfunction and death through cytoskeletal damage and oxidative stress.
  • Activated glial cells release neurotoxic factors like TNF-alpha in response to AGEs.
  • AGE-inhibitors have demonstrated efficacy in mitigating AGE-mediated complications in diabetes.

Conclusions:

  • Carbonyl stress from AGEs is a significant factor in Alzheimer's disease pathogenesis.
  • AGE-inhibitors represent a promising therapeutic strategy for Alzheimer's disease treatment.

More Related Videos

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...